Sunshine Acts, Cosmetic Procedures, and HIPAA Enforcement: A Round Up Of New Posts

The Reed Smith Life Sciences Legal Update blog has been updated to reflect a variety of recent developments of interest, including:

New posts to Life Sciences Legal Update

New posts are up on Life Sciences Legal Update regarding a Senate committee hearing on DTC ads for medical devices, the DOJ's revised its Principles of Federal Prosecution of Business Organizations, the business climate for pharmaceutical manufacturers, House Energy and Commerce Committee action on more than 7 health policy bills, and the overlooked implications of the FTC's Red Flag Regulations for the life sciences and health care industry. These posts, and more, are in keeping with the site's inter-disciplinary scope which is grounded in the recognition that legal issues are intertwined with business concerns, and rarely confine themselves to narrowly proscribed practice areas.

Welcome to Reed Smith's Life Sciences Legal Update blog

Over the years, the lawyers at Reed Smith who represent clients in the life sciences and health industry have published newsletters like Product Liability Update and Health Law Monitor to keep clients informed about key litigation, transactional, and regulatory developments. We now have decided to take advantage of a blog format to make our content more accessible (including search features and archives), and to make our delivery more efficient and environmentally conscious.

This site will have an inter-disciplinary scope, in keeping with the firm's recognition that legal issues are intertwined with business concerns, and rarely confine themselves to narrowly proscribed practice areas. It will be a collaborative effort by the firm’s Life Sciences Health Industry (LSHI) Group, which consists of 200 professionals, from many different practice areas, who are dedicated to serving clients who help save patients’ lives and preserve their health, whether through biotechnology, pharmaceuticals, medical devices, life sciences, or by delivering exceptional health care.

We also invite you to explore our companion blog, Health Industry Washington Watch, which focuses on legislative and regulatory developments affecting such areas as Medicare and Medicaid reimbursement; new benefits such as Medicare prescription drug coverage; and fraud and abuse developments.

We hope you will check our site often, and we welcome your feedback. To view more recent posts, please visit or return to our main page at http://www.lifescienceslegalupdate.com/.